Conduit Pharma receives Korean patent for its lead asset, AZD1656 targeting autoimmune diseases
Conduit Pharmaceuticals Inc., a dynamic, multi-asset clinical stage, life science company, announces that the Korean Intellectual Property Office (KIPO) has granted the composition of matter patent for its lead asset, AZD1656, a Glucokinase Activator …